论文部分内容阅读
作者研究了含有红霉素乙基琥珀酸酯和红霉素硬脂酸盐的两种市售儿科用混悬液的生物利用度,对不同年龄组进行了检查。受试者分二组:1～5周的新生儿13名,给予红霉素乙基琥珀酸酯混悬液(Abboticin)20毫克/公斤体重。在病房工作人员中暴发百日咳后,所有这些婴儿均给予红霉素40毫克/公斤/24小时;另一组46名1月～6岁婴幼儿给予红霉素乙基琥珀酸酯或红霉素硬脂酸盐(Reciomycin),按红霉素20毫克/公斤体重给
The authors studied the bioavailability of two commercially available pediatric suspensions containing erythromycin ethylsuccinate and erythromycin stearate and examined various age groups. Subjects were divided into two groups: 13 newborns from 1 to 5 weeks and 20 mg / kg body weight of erythromycin ethylsuccinate suspension (Abboticin). All of these infants were given erythromycin 40 mg / kg / 24 hours after outbreaks of pertussis among staff in the ward. Another 46 infants of 1 month to 6 years of age were given erythromycin ethylsuccinate or erythromycin Reciomycin is given as erythromycin 20 mg / kg body weight